MedPath

Randomized phase II syudy of weekly docetaxel versus S-1 and concurrent radiothrapy for stage III and IV laryngeal, oropharyngeal, and hypopharyngeal cancer in elderly patients or patients with complications

Phase 2
Conditions
laryngeal, oropharyngeal, and hypopharyngeal cancer
Registration Number
JPRN-UMIN000001144
Lead Sponsor
study group of chemoradiotherapy of the head and neck cancer
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1)with sever complications (for example ; malignant hypertension, congested heart failure, coronary insufficiency, myocardial infarction, angina pectoris, or abnormal cardiac rhythm which need to treat within 6 months, cerebrovascular accident within 6 months, cirrhosis, hemorrhagic gastrointestinal ulceration, diabetes that is loss of control, bleeding tendency) 2)with deverop fever and suspected infection 3)with motor palsy, peripheral neuropathy or edema (exclude the disorder which derives from primary disease) 4)with pleural effusion which need to treat or pericardial effusions 5)with active double cancer 6)pregnant or nursing women or women who like be pregnant 7)with interstitial pneumonitis which is revealed from chest X ray or chest CT 8)with a history of mental disorder or treated it at the moment 9)with sever allergy to docetaxel or S-1, or with a history of sever allergy 10)doctor's decision not to be registered to this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath